作者投稿
专家审稿
编辑办公
邮件订阅
RSS
-
摘要: 微生物组是人体的第二基因组，能够决定人的健康状态。微生物组研究促进了人类对微生物群体与人体、生态环境关系的新认识。对人体肠道微生物组的组成和功能进行系统研究，解析相关核心菌群的互作关系和调控机制，将为解决人类面临的健康问题带来革命性的理论创新，由此产生颠覆性的技术革新，有望为微生物组研究提供更好的解决方案。Abstract: The human microbiome, the second genome of the human body, can determine human health status. Microbiome research has prompted humans to re-understand the relationship between microbiota and individuals, as well as microbiota and the ecological environment. A comprehensive and systematic study of the structure and function of human gut microbiome and an analysis of the interaction and regulation mechanism of the relevant core bacteria will bring revolutionary theoretical innovations to solve the health problems of humans, and the resulting disruptive technological innovation has the potential to provide better solutions for microbiome research.
-
Keywords:
- microbiome /
- gut microbiota /
- disease /
- treatment
-
人们对缓和医疗的概念可能并不生疏，但对其认识尚且不够，对其理解抑或存在较大偏颇。无论是医生还是公众，都需要加深对缓和医疗重要性的认识，同时更深入地践行这一理念。
1. 人文理念是缓和医疗的本源
所谓缓和医疗，是指对慢性疾病、不可自愈/难以治愈之症、疾病晚期患者或年迈体弱者，医疗不力或救治无方，为尊重病患及其家人的意愿，为减轻其痛苦和症状，改善生命或生活质量的一种医疗对策[1]。
事实上，疾病晚期患者临近死亡(或称濒死)，是正常的生命过程。缓和医疗也是医疗过程，包含心理调适、营养支持、症状缓解、康复保健、改善预后、慰藉家人等，与延长生命并不矛盾。这些对策和措施，正是人文理念和人文关怀的体现，亦是医学及缓和医疗的本源[2]。正如特鲁多的墓志铭所阐述的，“有时是治愈，常常是帮助，而总是慰籍”。
“和缓是悉”，由来久矣。早在我国南朝，谢灵运的《山居赋》中即写道: “雷桐是别，和缓是悉”。雷、桐是古代的两位药学先祖，和、缓是古代两位名医，药神辨识草药之别，医圣明确病患之悉。尽管如此，面对诸多疾病，往往神药亦无力，圣医亦无方。此时，或者“古方治今病，和缓技亦穷”，或者人们还在留恋是否“如彼久病者，不敢忘和缓”还是“疏淪(音同药)费虽多，尺寸皆有功”呢？
于是，我们必须承认，此时最好的医疗是人文关怀，即“和缓是悉”。这就是医圣和、缓留给我们的无价财富与医疗真谛！
2. 缓和医疗是终极关怀的实施
缓和医疗涉及两个重要概念: 临终关怀(terminal care or hospice care)和终极关怀(ultimate concern)[3]。二者是不同的，临终关怀更侧重于具体的医疗措施，“临终”二字又显得狭隘、刺耳和难耐。而终极关怀则是对于生命的终极认识，比如生老病死、苦难痛殇。终极关怀其实是个哲学问题，亦是我们现今惯常的所谓“三观”(世界观、人生观、价值观)，这里侧重于对生命、身体、生活、健康、疾病与死亡的认识、理解和态度。这是每个人都必须面对，且必然要经历和选择的。
诞生或者死亡，发育或者缺陷，健康或者罹病，是科学的、生物学的、哲学的，也是自然的、宗教的、神秘的。医学当然要遵循自然规律和生命规律，但也有可能打破生死的自然轨迹，从而误导人类抗拒必然的生命过程。问题是作为医者，我们需要真正理解什么是生命的意义，以及什么是死亡的意义。现实中，我们确实在寻找消除病痛、延长生命的药物和方法，但也应该避免无意义的，甚至善意的扰乱。我们应该清楚地认识到，长生不老、无疾而终、健康长寿、万寿无疆，只不过是敬语和神话。
有了对于终极关怀的认识和理解，有了对于临终关怀的具体办法，我们对于缓和医疗就有了更深层次的认识和领会，也有助于更好地开展缓和医疗工作。可以认为，终极关怀是临终关怀或缓和医疗的目标和升华，临终关怀或缓和医疗是终极关怀的体现和实施。
3. 科学的认识论与医学的发展观
医学是一个复杂的认知系统，是自然科学与社会科学或人文科学的结合。其关乎国家、民族、社会、家庭、个人健康及幸福。所谓“天地神圣，生命至上”。为此，我们要实施全生命周期的健康管理。所谓全生命周期，就是从生到死的人生各个阶段。现阶段，缓和医疗可能更多实施于年长者，但在生命的各个阶段我们都会遇到不同的健康问题，缓和医疗理念在这些阶段具有同样重要的意义。
医学的认识和实践有两个明显的特征：一是局限性，二是风险性。所谓局限性，就是认知的局限，由于人体的复杂性以及人与环境(自然与社会)的交叉性，形成了诸多影响和变数。因此，我们对于疾病的认识和处理可能是局限的、片面的，甚至是错误的。二是风险性，因为医疗的对象是活的人体，诊断、治疗、药物、手术等都会有风险，是“危险的丛林”。先哲们告诫我们，临床工作“如临深渊，如履薄冰”，要“戒慎恐惧”。
近二三十年，医学在其他各个学科，特别是在遗传学、分子生物学、机械工艺学等技术的推动下，于颠簸中快速发展。诚然，技术的进步给医疗领域带来了巨大推动力，但也带来了诸多问题。过度诊断、过度治疗，过分相信和依赖机器检查及化验报告，脱离临床、脱离实际等的倾向日趋严重。数字化冲淡了医学的人文观念, 隔离了医生与患者，这给临床医学带来了巨大影响，却也进一步凸显了缓和医疗的重要性。
4. 小结
缓和医疗方兴未艾，可以说其是个幸运者，同时又是个逆行者。未来，缓和医疗必须紧密联系临床，既要走到患者床边去做面对面的具体工作，更要进行多学科协作，共同管理患者全生命周期各个阶段的各种问题。无论是大医院还是小诊所，缓和医疗都同样重要，都要践行和发展这一理念。北京协和医院是全国疑难重症诊疗中心，是医疗、教学和科研的结合与转化基地，应该在推动缓和医疗发展中发挥引领和示范作用，因此任重而道远。
缓和医疗不是一枝奇葩的花朵，而是一片关爱的森林。
作者贡献：方圆、潘元龙负责文献查阅、资料收集及论文撰写；朱宝利负责组织选题及论文审校。利益冲突：所有作者均声明不存在利益冲突 -
[1] Berg G, Rybakova D, Fischer D, et al. Microbiome definition re-visited: old concepts and new challenges[J]. Microbiome, 2020, 8: 103. DOI: 10.1186/s40168-020-00875-0
[2] 段云峰, 王升跃, 陈禹保, 等. 微生物组测序与分析专家共识[J]. 生物工程学报, 2020, 36: 2516-2524. https://www.cnki.com.cn/Article/CJFDTOTAL-SHWU202012003.htm [3] Zhao L. Genomics: The tale of our other genome[J]. Nature, 2010, 465: 879-880. DOI: 10.1038/465879a
[4] Riesenfeld CS, Schloss PD, Handelsman J. Metagenomics: genomic analysis of microbial communities[J]. Annu Rev Genet, 2004, 38: 525-552. DOI: 10.1146/annurev.genet.38.072902.091216
[5] Integrative HMPRNC. The Integrative Human Microbiome Project: dynamic analysis of microbiome-host omics profiles during periods of human health and disease[J]. Cell Host Microbe, 2014, 16: 276-289. DOI: 10.1016/j.chom.2014.08.014
[6] Integrative HMPRNC. The Integrative Human Microbiome Project[J]. Nature, 2019, 569: 641-648. DOI: 10.1038/s41586-019-1238-8
[7] Li J, Jia H, Cai X, et al. An integrated catalog of reference genes in the human gut microbiome[J]. Nat Biotechnol, 2014, 32: 834-841. DOI: 10.1038/nbt.2942
[8] Qin J, Li R, Raes J, et al. A human gut microbial gene catalogue established by metagenomic sequencing[J]. Nature, 2010, 464: 59-65. DOI: 10.1038/nature08821
[9] Sinha R, Abu-Ali G, Vogtmann E, et al. Assessment of variation in microbial community amplicon sequencing by the Microbiome Quality Control (MBQC) project consortium[J]. Nat Biotechnol, 2017, 35: 1077-1086. DOI: 10.1038/nbt.3981
[10] Relman DA. The human microbiome: ecosystem resilience and health[J]. Nutr Rev, 2012, 70: S2-S9. DOI: 10.1111/j.1753-4887.2012.00489.x
[11] Eckburg PB, Bik EM, Bernstein CN, et al. Diversity of the human intestinal microbial flora[J]. Science, 2005, 308: 1635-1638. DOI: 10.1126/science.1110591
[12] Turnbaugh PJ, Ley RE, Mahowald MA, et al. An obesity-associated gut microbiome with increased capacity for energy harvest[J]. Nature, 2006, 444: 1027-1031. DOI: 10.1038/nature05414
[13] Human Microbiome Project C. Structure, function and diversity of the healthy human microbiome[J]. Nature, 2012, 486: 207-214. DOI: 10.1038/nature11234
[14] Lloyd-Price J, Mahurkar A, Rahnavard G, et al. Strains, functions and dynamics in the expanded Human Microbiome Project[J]. Nature, 2017, 550: 61-66. DOI: 10.1038/nature23889
[15] Ruhlemann MC, Hermes BM, Bang C, et al. Genome-wide association study in 8, 956 German individuals identifies influence of ABO histo-blood groups on gut microbiome[J]. Nat Genet, 2021, 53: 147-155. DOI: 10.1038/s41588-020-00747-1
[16] Qin Y, Havulinna AS, Liu Y, et al. Combined effects of host genetics and diet on human gut microbiota and incident disease in a single population cohort[J]. Nat Genet, 2022, 54: 134-142. DOI: 10.1038/s41588-021-00991-z
[17] De Filippis F, Pellegrini N, Vannini L, et al. High-level adherence to a Mediterranean diet beneficially impacts the gut microbiota and associated metabolome[J]. Gut, 2016, 65: 1812-1821. DOI: 10.1136/gutjnl-2015-309957
[18] Meslier V, Laiola M, Roager HM, et al. Mediterranean diet intervention in overweight and obese subjects lowers plasma cholesterol and causes changes in the gut microbiome and metabolome independently of energy intake[J]. Gut, 2020, 69: 1258-1268. DOI: 10.1136/gutjnl-2019-320438
[19] Rinott E, Meir AY, Tsaban G, et al. The effects of the Green-Mediterranean diet on cardiometabolic health are linked to gut microbiome modifications: a randomized controlled trial[J]. Genome Med, 2022, 14: 29. DOI: 10.1186/s13073-022-01015-z
[20] Zeevi D, Korem T, Zmora N, et al. Personalized Nutrition by Prediction of Glycemic Responses[J]. Cell, 2015, 163: 1079-1094. DOI: 10.1016/j.cell.2015.11.001
[21] Rosario D, Bidkhori G, Lee S, et al. Systematic analysis of gut microbiome reveals the role of bacterial folate and homocysteine metabolism in Parkinson's disease[J]. Cell Rep, 2021, 34: 108807. DOI: 10.1016/j.celrep.2021.108807
[22] Moreno-Indias I, Lahti L, Nedyalkova M, et al. Statistical and Machine Learning Techniques in Human Microbiome Studies: Contemporary Challenges and Solutions[J]. Front Microbiol, 2021, 12: 635781. DOI: 10.3389/fmicb.2021.635781
[23] Gacesa R, Kurilshikov A, Vich Vila A, et al. Environ-mental factors shaping the gut microbiome in a Dutch population[J]. Nature, 2022, 604: 732-739. DOI: 10.1038/s41586-022-04567-7
[24] Qin N, Yang F, Li A, et al. Alterations of the human gut microbiome in liver cirrhosis[J]. Nature, 2014, 513: 59-64. DOI: 10.1038/nature13568
[25] Zhang X, Zhang D, Jia H, et al. The oral and gut microbiomes are perturbed in rheumatoid arthritis and partly normalized after treatment[J]. Nat Med, 2015, 21: 895-905. DOI: 10.1038/nm.3914
[26] Ramos A, Hemann MT. Drugs, Bugs, and Cancer: Fusobacterium nucleatum Promotes Chemoresistance in Colorectal Cancer[J]. Cell, 2017, 170: 411-413. DOI: 10.1016/j.cell.2017.07.018
[27] Tsoi H, Chu ESH, Zhang X, et al. Peptostreptococcus anaerobius Induces Intracellular Cholesterol Biosynthesis in Colon Cells to Induce Proliferation and Causes Dysplasia in Mice[J]. Gastroenterology, 2017, 152: 1419-33. e5. DOI: 10.1053/j.gastro.2017.01.009
[28] Zou Y, Xue W, Luo G, et al. 1, 520 reference genomes from cultivated human gut bacteria enable functional microbiome analyses[J]. Nat Biotechnol, 2019, 37: 179-185. DOI: 10.1038/s41587-018-0008-8
[29] Ji P, Zhang Y, Wang J, et al. MetaSort untangles metagenome assembly by reducing microbial community complexity[J]. Nat Commun, 2017, 8: 14306. DOI: 10.1038/ncomms14306
[30] Peng G, Ji P, Zhao F. A novel codon-based de Bruijn graph algorithm for gene construction from unassembled transcriptomes[J]. Genome Biol, 2016, 17: 232. DOI: 10.1186/s13059-016-1094-x
[31] He S, Huang Z, Wang X, et al. SOAPMetaS: profiling large metagenome datasets efficiently on distributed clusters[J]. Bioinformatics, 2021, 37: 1021-1023. DOI: 10.1093/bioinformatics/btaa697
[32] Hattori N, Yamashiro Y. The Gut-Brain Axis[J]. Ann Nutr Metab, 2021, 77: 1-3.
[33] Mayer EA, Nance K, Chen S. The Gut-Brain Axis[J]. Annu Rev Med, 2022, 73: 439-453. DOI: 10.1146/annurev-med-042320-014032
[34] Silveira MAD, Bilodeau S, Greten TF, et al. The gut-liver axis: host microbiota interactions shape hepatocarcinogenesis[J]. Trends Cancer, 2022 8: 583-597. DOI: 10.1016/j.trecan.2022.02.009
[35] He Y, Wen Q, Yao F, et al. Gut-lung axis: The microbial contributions and clinical implications[J]. Crit Rev Microbiol, 2017, 43: 81-95. DOI: 10.1080/1040841X.2016.1176988
[36] Zhao L, Zhang F, Ding X, et al. Gut bacteria selectively promoted by dietary fibers alleviate type 2 diabetes[J]. Science, 2018, 359: 1151-1156. DOI: 10.1126/science.aao5774
[37] Coutzac C, Jouniaux JM, Paci A, et al. Systemic short chain fatty acids limit antitumor effect of CTLA-4 blockade in hosts with cancer[J]. Nat Commun, 2020, 11: 2168. DOI: 10.1038/s41467-020-16079-x
[38] Vetizou M, Pitt JM, Daillere R, et al. Anticancer immunotherapy by CTLA-4 blockade relies on the gut microbiota[J]. Science, 2015, 350: 1079-1084. DOI: 10.1126/science.aad1329
[39] Routy B, Le Chatelier E, Derosa L, et al. Gut microbiome influences efficacy of PD-1-based immunotherapy against epithelial tumors[J]. Science, 2018, 359: 91-97. DOI: 10.1126/science.aan3706
[40] Mao J, Wang D, Long J, et al. Gut microbiome is associated with the clinical response to anti-PD-1 based immunotherapy in hepatobiliary cancers[J]. J Immunother Cancer, 2021, 9: e003334. DOI: 10.1136/jitc-2021-003334
[41] Mcculloch JA, Davar D, Rodrigues RR, et al. Intestinal microbiota signatures of clinical response and immune-related adverse events in melanoma patients treated with anti-PD-1[J]. Nat Med, 2022, 28: 545-556. DOI: 10.1038/s41591-022-01698-2
[42] Yi Y, Shen L, Shi W, et al. Gut Microbiome Components Predict Response to Neoadjuvant Chemoradiotherapy in Patients with Locally Advanced Rectal Cancer: A Prospective, Longitudinal Study[J]. Clin Cancer Res, 2021, 27: 1329-1340. DOI: 10.1158/1078-0432.CCR-20-3445
[43] Shen S, Lim G, You Z, et al. Gut microbiota is critical for the induction of chemotherapy-induced pain[J]. Nat Neurosci, 2017, 20: 1213-1216. DOI: 10.1038/nn.4606
[44] Tian J, Bai B, Gao Z, et al. Alleviation Effects of GQD, a Traditional Chinese Medicine Formula, on Diabetes Rats Linked to Modulation of the Gut Microbiome[J]. Front Cell Infect Microbiol, 2021, 11: 740236. DOI: 10.3389/fcimb.2021.740236
[45] Juul FE, Garborg K, Bretthauer M, et al. Fecal Microbiota Transplantation for Primary Clostridium difficile Infection[J]. N Engl J Med, 2018, 378: 2535-2536. DOI: 10.1056/NEJMc1803103
[46] Kassam Z, Dubois N, Ramakrishna B, et al. Donor Screening for Fecal Microbiota Transplantation[J]. N Engl J Med, 2019, 381: 2070-2072. DOI: 10.1056/NEJMc1913670
[47] Siegmund B. Is intensity the solution for FMT in ulcerative colitis?[J]. Lancet, 2017, 389: 1170-1172. DOI: 10.1016/S0140-6736(17)30313-6
[48] Van Rossum T, Ferretti P, Maistrenko OM, et al. Diversity within species: interpreting strains in microbiomes[J]. Nat Rev Microbiol, 2020, 18: 491-506. DOI: 10.1038/s41579-020-0368-1
计量
- 文章访问数: 5323
- HTML全文浏览量: 1447
- PDF下载量: 469
下载:
